Duloxetine (Cymbalta)
What studies of Duloxetine (Cymbalta) found
At a glance, by condition
Long COVID: D Little or no difference
Based on the strongest evidence, compared with another group, not randomised (very low certainty), for overall symptoms.
1 outcome rated · see each below
ME/CFS: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group (very low certainty): 2 findings, all C.
2 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: For long COVID, studies found little or no difference with Duloxetine (Cymbalta). For ME/CFS, Duloxetine (Cymbalta) might help some people, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- Duloxetine (Cymbalta) · ME/CFS is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- Duloxetine (Cymbalta) · Long COVID is hereDLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Long COVID
Daily life and health overall
Overall symptoms1 study · 17 people took Duloxetine (Cymbalta) Little or no difference D
Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the change wasn't shown to be more than chance.
Compared with another group, not randomised108 in the study · at least 1 month after starting treatment · 20–120 mg daily
No clear difference in overall symptoms.
The evidence is very uncertain about the effect of duloxetine (Cymbalta) on overall symptoms in long COVID. Little or no difference · very low certainty D
- Serious risk of bias (ROBINS-I)
- The change wasn't shown to be more than chance
See the 1 study
-
Low-dose Naltrexone Improves post-COVID-19 condition Symptoms. (2024)
- People in the study
- 108 in the study
- Dose
- 20–120 mg daily
- Outcome
- Adjusted models for improvement by treatment: Duloxetine
- Effect
- no clear difference
- Risk of bias
ROBINS-I: Serious
- Confounding
- Moderate. adjusted for: age, Charlson Comorbidity Index score and prior COVID-19 hospitalization
Adjusted for age, Charlson Comorbidity Index score and prior COVID-19 hospitalization.
- Selection of participants
- Moderate. comparison group: non-randomised; physical therapy group required receiving physical therapy and not taking medications; medication plus physical therapy classified by medication
To be included in the physical therapy group, patients needed to be receiving physical therapy and not taking any of the medications described previously.
- Classification of interventions
- Moderate. from records after the fact
- Deviations from intended interventions
- NI. not reported for this design
- Missing data
- Moderate. missing data: per-arm not analysed not reported; incomplete data for inflammatory markers
we had incomplete data for the analysis of inflammatory markers.
- Measurement of outcomes
- Serious. self-reported by people who knew their treatment
- Selection of the reported result
- Moderate. a pre-specified primary outcome
ME/CFS
Daily life and health overall
Daily functioning1 study · 1 (few people) person took Duloxetine (Cymbalta) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · Twelve months later · 120 mg/d, continuous medication (few people)
Daily functioning improved.
The evidence is very uncertain about the effect of duloxetine (Cymbalta) on daily functioning in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
See the 1 study
-
Successful treatment of chronic fatigue syndrome with duloxetine and trijodthyronine--a case study. (2008)
- People in the study
- 1 in the study
- Dose
- 120 mg/d, continuous medication
- Outcome
- improvement in overall function at twelve months
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Overall symptoms1 study · 1 (few people) person took Duloxetine (Cymbalta) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · Twelve months later · 120 mg/d, continuous medication (few people)
Overall symptoms improved.
The evidence is very uncertain about the effect of duloxetine (Cymbalta) on overall symptoms in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
See the 1 study
-
Successful treatment of chronic fatigue syndrome with duloxetine and trijodthyronine--a case study. (2008)
- People in the study
- 1 in the study
- Dose
- 120 mg/d, continuous medication
- Outcome
- alleviation of psychic and somatic symptoms with combination therapy
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Side effects
Stopping because of side effects2 studies
3 in the duloxetine group [10%] and 0 in the placebo group; P 1⁄4 0.24 using the Fisher exact test
A randomized, placebo-controlled, double-blinded trial of duloxetine in the treatment of general fatigue in patients with chronic fatigue syndrome. (2015)discontinuation of the drug along with administration of G-CSF
Risk of Neutropenia Associated With Duloxetine: A Case Study of an 80-Year-Old Man With Depression Related to Long COVID. (2025)
Side effects studies reported6 kinds
| Side effect | Studies that reported it |
|---|---|
| Anxiety or irritability | 1 study |
| Dizziness | 1 study |
| Headache | 1 study |
| Nausea or stomach upset | 1 study |
| Trouble sleeping | 1 study |
| Vivid dreams or nightmares | 1 study |
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
30 mg at the start in most studies
- 2Raise
Raised step by step in 3 of 4 studies
- 3Top dose
Most often 120 mg (3 of 4 studies)
Doses across 4 studies
20 to 120 mg.
Each study’s dose, as printed
- 60–120 mg/d, titrated 30 mg once a day for 1 week, then 60 mg once a day for the next 3 weeks, then 90 mg once a day for the next 4 weeks, then 120 mg once a day if tolerated until the end of the 12 weeks A randomized, placebo-controlled, double-blinded trial of duloxetine in the treatment of general fatigue in patients with chronic fatigue syndrome. (2015)
- 20–120 mg daily Low-dose Naltrexone Improves post-COVID-19 condition Symptoms. (2024)
- 120 mg/d, continuous medication Successful treatment of chronic fatigue syndrome with duloxetine and trijodthyronine--a case study. (2008)
- 60 mg/day, later reduced to 30 mg/day Overlapping Post-COVID Conditions: A Case of Myalgic Encephalomyelitis and Postural Orthostatic Tachycardia Syndrome Triggered by Sequential Epstein-Barr Virus (EBV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections. (2026)
All papers
- Low-dose Naltrexone Improves post-COVID-19 condition Symptoms.2024 · compared with another group · 108 in the study
Summary
This retrospective cohort study asked whether treatments adapted from ME/CFS improve symptoms and inflammatory markers in post–COVID-19 condition at the Miami Veterans Affairs post–COVID-19 clinic. It included 108 patients who started PCC treatments and had at least 2 follow-up visits; the treatment groups were low-dose naltrexone (n = 24; 1.5–4.5 mg daily), amitriptyline (n = 41; 10–20 mg daily), duloxetine (n = 17; 20–120 mg daily), and physical therapy alone (n = 26). Treatment duration was not reported; improvement was defined at least 1 month after starting treatment. Median follow-up was 147 (58–264) days for low-dose naltrexone, 250 (120–310) days for amitriptyline, 174 (36–241) days for duloxetine, and 101 (43–152) days for physical therapy. Improvement in at least 1 of fatigue, pain, brain fog, or dyspnea was reported by 67% taking low-dose naltrexone, 61% taking amitriptyline, 41% receiving physical therapy alone, and 35% taking duloxetine. The adjusted relative hazard of improvement for low-dose naltrexone versus physical therapy alone was 5.04 (95% CI, 1.22–20.77; P = 0.02). Amitriptyline (2.68; 0.80–8.97; P = 0.10) and duloxetine (0.82; 0.17–3.85; P = 0.81) did not significantly improve over physical therapy. Symptom reports: low-dose naltrexone for fatigue and pain; amitriptyline and duloxetine for fatigue; physical therapy for dyspnea and fatigue. The text states low-dose naltrexone decreased C-reactive protein and increased cortisol and other treatments did not, while Table 4 also lists changes for duloxetine; all biomarker changes were nonsignificant (P > 0.05). Harms and withdrawals were not reported.
- Risk of Neutropenia Associated With Duloxetine: A Case Study of an 80-Year-Old Man With Depression Related to Long COVID.2025 · no comparison group
Summary
This case study describes an 80-year-old man with depression in long COVID who was treated with duloxetine. According to the authors, the case shows that duloxetine can be associated with FN (the title speaks of neutropenia), and that stopping the drug together with giving G-CSF is part of managing it. The short text does not report how his depression changed or how long he took the drug.
- Longitudinal Progression of Patients with Long COVID Treated in a Post-COVID Clinic: A Cross-Sectional Survey.2024 · no comparison group · 852 in the study · 536 with outcome data
Summary
This cross-sectional follow-up survey asked patients with long COVID seen at a post-COVID clinic (PCoCC) about symptoms and treatments. A total of 852 patients were identified; 536 completed the survey. The mean time from COVID-19 infection to survey completion was 23.2 ± 6.4 months. There was no comparison group; patients rated symptoms at the initial clinic visit (baseline, by recall) and at follow-up on a 1-10 scale, and rated whether treatments were helpful. Surveyed treatments included low-dose naltrexone, vagal nerve stimulator, midodrine, fludrocortisone, pyridostigmine, aripiprazole, plasmapheresis, reishi mushroom and nattokinase/serrapeptase; treatment duration was not reported. Overall functioning median improved from 8 (6, 9) at baseline to 5 (3, 8) at follow-up (P < .001); fatigue improved from 8 (7,10) to 6 (3, 8) and brain fog from 8 (6, 9) to 5 (3, 8) (P < .001 for both). All individual symptoms assessed were significantly improved (P < .001). Only 4.5% (24/536) had recovered completely. Helpful ratings included low-dose naltrexone 45/77 (58%), vagal nerve stimulator 18/34 (53%), plasmapheresis 9/9 (100%), midodrine 7/17 (41%), fludrocortisone 8/17 (47%), pyridostigmine 2/3 (67%), aripiprazole 8/17 (47%), reishi mushroom 8/19 (42%) and nattokinase/serrapeptase 5/9 (56%). A minority worsened in overall function and in fatigue, myalgia and orthostasis; counts, side-effect counts, and withdrawals due to harms were not reported.
- Use of Neuromodulation to Treat Post-COVID Neuropathic Pain: A Case Report.2024 · case report · 1 in the study
Summary
This case report describes one 27-year-old man with bilateral upper-extremity neuropathic pain that began with a severe COVID-19 infection about 2 years before presentation. There was no comparison group; reports are before and after treatment in this one patient. He had occupational therapy and trials of amlodipine, sildenafil, gabapentin, duloxetine, and low-dos naltrexone 4.5 mg daily, and a stellate ganglion block, which he said gave no noticeable benefit. He then received a Nevro device with cervical lead placement. A single lead trial with the tip at the C2/C3 interspace gave excellent relief, with a >70% decrease in baseline pain, improved functionality, and increased ability to participate in physical therapy. At implant, two leads were placed, one at C2/C3 and one staggered at C3. More than 6 months after surgery, he reported a 50% improvement in baseline pain and improved functionality, including lifting weights and repetitive motions; he recovered more quickly from pain flares and was quite pleased with the device. Gabapentin seemed most helpful, but he had dosis-limiting side effects, including lethargy. No harms were reported for the device. The authors state limits of case reports: lack of generalisability, inability to establish cause and effect, retrospective design, and potential for overinterpretation.
- Stellate Ganglion Block for the treatment of olfactory and gustatory dysfunction in patients with Long COVID: Case Series2023 · case report · 2 in the study
Summary
This case series reports two patients with Long COVID and olfactory and gustatory complaints who presented to the authors’ clinic. Both received stellate ganglion block (SGB) with 6 ml solution containing bupivacaine (15mg) and triamcinolone (10mg), given right-sided then left-sided 48 hours apart; the second patient had the bilateral procedure repeated. Severity of complaints was rated on a numerical rating scale (NRS) from 0 to 10 before and after SGB. At 2 months after the procedure in Case 1, cacosmia and cacogeusia each changed from 10 to 1 (90% achieved improvement), fatigue from 7 to 0 (100%), impaired concentration from 8 to 1 (87,5%), sleep disturbance from 6 to 1 (83,3%), myalgia from 7 to 2 (71,4%), and headache from 5 to 0 (100%). At 2 months after the second procedure in Case 2, anosmia changed from 8 to 5 (37,5%), ageusia from 7 to 4 (42,9%), myalgia from 3 to 1 (66,7%), and headache from 2 to 0 (100%). The text reports 90% recovery in the first patient and around 40% recovery in the second patient. Horner’s syndrome developed in both cases. There was no comparison group. The authors state evidence is limited by a few case reports and call for well-designed, multicenter studies.
- Successful Treatment of Post-influenza Chronic Fatigue Syndrome with Kampo Medicine : a Case Report2014 · case report · 1 in the study
Summary
This case report described one patient with post-influenza chronic fatigue syndrome, referred to an outpatient Kampo clinic. The patient was reported as a 16-year-old high school student in the abstract and as 15 years old in the case section. No comparison group was reported. Treatment was a combination of Kampo medicine (sanoshashinto) and duloxetine. At 4 weeks, malaise and fatigue improved, but fever and anorexia remained; in the case text, fatigue/malaise was reduced at 4 weeks while the fever pattern was unchanged and appetite loss was reported. The Kampo medicine was changed and hochuekkito was added; the abstract states this addition dramatically ameliorated his symptoms. At 8 weeks, the fever pattern improved and appetite and will improved. At 12 weeks, subjective and clinical symptoms were improved, and the patient returned to school in September X. At July X+1, sanoshashinto, hochuekkito and duloxetine were continued. Appetite loss was the recorded harm; withdrawals due to harms were not reported. The authors state that consent for imaging was not obtained, so axillary lymph node and spleen swelling could not be confirmed on imaging.
- Successful treatment of chronic fatigue syndrome with duloxetine and trijodthyronine--a case study.2008 · case report · 1 in the study
Summary
This case study reports one 26-year-old woman (Ms A) with chronic fatigue syndrome (cFS). No comparison group was used. She first received acyclovir 1.5 g/d for 10 days, which did not lead to clinical improvement, and amantadine 50 mg/d; in approximately 2 weeks tiredness and low energy improved, whereas myalgia did not change. Duloxetine was then given at 120 mg/d. Under duloxetine, most symptoms of cFS disappeared within 4 weeks and no adverse drug effects occurred; first improvements were a complete remission in body myalgia and a reduction in difficulties to concentrate in less than 4 weeks. Three months later, under continuous medication with duloxetine, she developed a relapse with daily somnolence, a strong feeling of tiredness, and the feeling of low energy; myalgia did not reappear. Trijodthyronine 20 2g/d was added to continuing duloxetine. Within 2 weeks, all symptoms disappeared almost completely. Twelve months later, she still continued to show improvement in her overall function. The authors do not state limitations.
- Overlapping Post-COVID Conditions: A Case of Myalgic Encephalomyelitis and Postural Orthostatic Tachycardia Syndrome Triggered by Sequential Epstein-Barr Virus (EBV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections.2026 · combination: given with other treatments · 1 in the study
Summary
This case report describes one 48-year-old woman in Belo Horizonte, Minas Gerais, Brazil, followed at the Carlos Prates Health Center as part of VITA Monitoring. She had ME/CFS diagnosed in early 2023 and POTS diagnosed later that year after SARS-CoV-2 infection in January 2022, with PCC persisting over three years. Her regimen included pyridostigmine bromide 60 mg every 12 hours, duloxetine hydrochloride 60 mg/day (later 30 mg/day), naltrexone 2 mg/day, bupropion 300 mg/day, palmitoylethanolamide 600 mg/day (later 900 mg/day and 1200 mg/day), vitamin C 1 g/day, Omega-3, pacing, hydroxyzine hydrochloride 25 mg/day, methylprednisolone 125 mg/day for three days, and vitamin B12 1 mg/day. Follow-up was baseline (V1) and evaluations after one month (1M), three months (3M), six months (6M), and twelve months (12M). There was no comparison group and no randomisation. The report states partial improvement in fatigue, orthostatic symptoms, and memory, but worsening of hair loss; worsening of symptoms after starting light walks (10 minutes/day); and treatment responses that were partial and fluctuating, with no objective biomarkers available to quantify them. Final assessment in mid-2025 indicated partial, fluctuating symptom response and persistent functional impairment. Harms reported were worsening hair loss and worsening symptoms after starting light walks; withdrawals for harms were not reported. Table 1 presents anthropometric, vital-sign, and handgrip strength measurements descriptively; the authors state changes should not be interpreted as evidence of a treatment effect.
- Interventions for Long COVID: A Narrative Review.2025 · review
Summary
This narrative review synthesized evidence from 97 studies (n=8260, 103 publications) on interventions for common long COVID symptoms: fatigue, neurocognitive symptoms, anxiety, depression, and sleep issues. The review included randomized and non-randomized studies and compared medications, rehabilitation, behavioral and mind-body programs, supplements, complementary treatments, and COVID-19 vaccination with placebo, usual care, no treatment, or other active comparators. For vortioxetine versus placebo, one RCT (n = 141) reported a significant reduction in depression symptoms (adjMD of −1.52; 95% CI −2.85 to −0.19) and improvement in quality of life (WHO-5, adjMD of 2.36; 95% CI 0.77 to 3.94), with mixed cognitive results. An RCT of “Fit after COVID” CBT (n=114) reported improvement in fatigue (CIS-fatigue: MD −8.8; 95% CI −11.9 to −5.8), cognitive impairment (CIS-concentration: MD −5.1; 95% CI −6.9 to −3.4), and physical function (SF-36-Physical Health: MD 7.1; 95% CI 2.9 to 11.3). Hyperbaric oxygen therapy (n=73) improved fatigue (SF-36 energy subscale, 18.2 vs 6.0, p=0.029) and sleep quality (PSQI, 8.1 vs 9.2, p=0.042) versus sham. Transcranial direct current stimulation (n=47) reduced physical fatigue (MFIS-Physical: p=0.034) but not overall fatigue (MFIS-Total: p=0.184). A COVID-19 vaccine study (n=453) found no statistically significant difference in fatigue, depression, or sleep quality. Adverse events included treatment-related reactions with vortioxetine (26.8% vs. 22.1%), non-serious adverse events with AXA1125 (RR 2.62, 95% CI 1.00 to 6.89), and similar adverse event rates with SIM01 (10% vs. 11%; p=0.63).
- The potential therapeutic approaches targeting gut health in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): a narrative review.2025 · review
Summary
This narrative review searched English peer-reviewed literature from January 1995 to January 2025 via PubMed, Scopus, and Web of Science to synthesize data on gut microbiota, inflammatory markers, and therapeutic outcomes in ME/CFS. The review did not report enrolling patients. It describes probiotic studies: an Italian pilot 8-week course improved well-being and reduced inflammation; in 15 ME/CFS patients, three strains improved neurocognitive function but no significant fatigue or physical activity reduction in only nine patients; Bifidobacterium infantis 35,624 in 48 patients lowered CRP, TNF-α, and IL-6. A 12-week Ubiquinol-10 randomized trial reported no significant fatigue improvement but reduced night-time awakenings; a 16-week randomized placebo-controlled trial of oral melatonin (1 mg) and zinc (10 mg) in 50 patients showed reductions in physical fatigue and improved quality of life. FMT: a retrospective study of 60 patients reported 70% response after four weeks and 58% maintained resolution for 15–20 years; another reported 17 of 21 patients with at least 60% improvement; a randomized placebo-controlled pilot in 11 patients (5 universal donor, 6 autologous) found no notable quality-of-life differences at 1 and 6 months. A Norway survey reported about 80% declined after graded exercise therapy; structured moderate activity over 12 to 26 weeks reduced fatigue compared with conventional/passive therapies; after a maximal exercise test, pain, fatigue, and confusion changed, with Clostridium in blood at 15 min and Bacilli increased at 48 h. Authors state current research lacks comprehensive insights and studies often produce conflicting findings, with varied diagnostic criteria and small samples.
- Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants.2009 · review
Summary
This review did not run its own trial; it summarized published data on pharmacological treatment of chronic fatigue syndrome (CFS), identified through a PubMed literature search. The review covers antidepressants and other psychotropic agents in CFS. In included randomized, placebo-controlled trials, moclobemide vs. placebo (47 vs. 43) showed clinically global improvement 51 vs. 33% (OR = 2.16); KPI mean difference between two groups was 0.28 favoring MCB, and Vigor subscale on POMS mean difference was 0.51 favoring MCB. Overall response by subjective global impression was 51% with moclobemide vs. 23% with placebo. At 12 weeks, MIR failed to separate from PBO on FS; at 24 weeks, CBT + MIR showed significantly more reduction in FS scores than PBO + CBT, with an observed difference of 5.5 (95% CI = 15.4 – 22), whereas MIR + CBT failed to separate from PBO + CBT. Fluoxetine failed to separate from PBO on SFS and BDI scores, and failed to demonstrate benefit on listed outcome measures. The review lists harms: TCAs potentially induce sedation and orthostatic hypotension; MAOIs have hypertensive crisis; stimulant medications carry risks of misuse, abuse, withdrawal, and diversion. Authors state research does not support definitive conclusions about antidepressant efficacy in CFS.